-
To establish whether or not the company
had freedom to operate without accessing the patent estate.
-
To identify and cost out other viable
options, including the risk and cost of litigation.
-
To confirm the value of the IP acquisition
to the company in terms of:
-
To provide the Board and regulators
with an independent review of the purchase price, how
it was justified internally and whether such justification
was reasonable.
-
To benchmark the deal, including milestone
and royalty rates, against similar technology access deals.
The programme of work
-
A review and analysis of the key technology
platform, related intellectual property, licences and
cross licences.
-
Examination and benchmarking of deal
terms against other relevant technology access deals in
the biosciences field.
-
Creation of an epidemiological and market
forecast for four separate therapeutic fields (ovarian
cancer, small cell lung cancer, non Hodgkin's lymphoma
and rheumatoid arthritis).
-
Commercial evaluation of the company's
lead development products in these therapeutic areas (market
share and revenue).
-
Creation of a probability based Net
Present Value (NPV) valuation model for the IP acquisition
and alternative strategies identified by Bridgehead Consulting.
|
|
The
deliverables to the client |
-
A comprehensive report addressing
the company's stated objectives above.
-
The report was subsequently included
in the "Auditors Report" to gain regulatory
clearance for the deal.
-
A tailor made probability-based
NPV model covering the major elements of the company's
current business activities.
|
| |
The
project achievements |
|
Added value
In addition to providing the client
with an independent endorsement and valuation of a critical
multi-million dollar IP acquisition, the project provided
a third party assessment of the company's key technology
platforms, lead development products and commercial
strategy as well as providing an assessment of the key
markets into which the company will go.
|
| |
|
PDF Version